

François Goldwasser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5807285/publications.pdf>

Version: 2024-02-01

122
papers

2,103
citations

331670

21
h-index

302126

39
g-index

128
all docs

128
docs citations

128
times ranked

3129
citing authors

#	ARTICLE	IF	CITATIONS
1	Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma. PLoS ONE, 2012, 7, e37563.	2.5	252
2	Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. European Journal of Cancer, 2015, 51, 45-54.	2.8	131
3	Use of platinum derivatives during pregnancy. Cancer, 2008, 113, 3069-3074.	4.1	120
4	Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology?. , 2019, 196, 135-159.		100
5	Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy ., American Journal of Clinical Nutrition, 2017, 105, 1139-1147.	4.7	74
6	Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. Investigational New Drugs, 2017, 35, 436-441.	2.6	73
7	Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib. Clinical Pharmacokinetics, 2019, 58, 451-467.	3.5	72
8	Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. Cancers, 2020, 12, 473.	3.7	72
9	Malnutrition in Patients With Cancer: Comparison of Perceptions by Patients, Relatives, and Physiciansâ€”Results of the NutriCancer2012 Study. Journal of Parenteral and Enteral Nutrition, 2018, 42, 255-260.	2.6	71
10	Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug Design, Development and Therapy, 2017, Volume 11, 2801-2811.	4.3	54
11	Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients. Journal of Pharmaceutical and Biomedical Analysis. 2018, 158, 174-183.	2.8	50
12	Unmet needs in clinical nutrition in oncology: a multinational analysis of real-world evidence. Therapeutic Advances in Medical Oncology, 2020, 12, 175883591989985.	3.2	42
13	Diagnostic criteria for cancer cachexia: reduced food intake and inflammation predict weight loss and survival in an international, multiâ€œohort analysis. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 1189-1202.	7.3	41
14	Effect of integrated palliative care on the quality of end-of-life care: retrospective analysis of 521 cancer patients. BMJ Supportive and Palliative Care, 2012, 2, 239-247.	1.6	38
15	Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients. Journal of Pharmaceutical and Biomedical Analysis, 2017, 139, 30-36.	2.8	35
16	NutriCancer: A French observational multicentre cross-sectional study of malnutrition in elderly patients with cancer. Journal of Geriatric Oncology, 2018, 9, 74-80.	1.0	32
17	The impact of body composition parameters on severe toxicity of nivolumab. European Journal of Cancer, 2020, 124, 170-177.	2.8	32
18	Creatinine-to-cystatin C ratio and bioelectrical impedance analysis for the assesement of low lean body mass in cancer patients: Comparison to L3â€œcomputed tomography scan. Nutrition, 2021, 81, 110895.	2.4	32

#	ARTICLE	IF	CITATIONS
19	Multicentre analysis of intensity of care at the end-of-life in patients with advanced cancer, combining health administrative data with hospital records: variations in practice call for routine quality evaluation. <i>BMC Palliative Care</i> , 2019, 18, 35.	1.8	29
20	Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?. <i>Cancers</i> , 2019, 11, 1784.	3.7	28
21	Resting energy expenditure in the risk assessment of anticancer treatments. <i>Clinical Nutrition</i> , 2018, 37, 558-565.	5.0	25
22	Mental disorders associated with recent cancer diagnosis: Results from a nationally representative survey. <i>European Journal of Cancer</i> , 2018, 105, 10-18.	2.8	23
23	Feasibility of Gemcitabine plus Oxaliplatin in Advanced Hepatocellular Carcinoma Patients with Child-Pugh B Cirrhosis. <i>Oncology</i> , 2013, 84, 32-38.	1.9	22
24	Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study. <i>Fundamental and Clinical Pharmacology</i> , 2018, 32, 98-107.	1.9	22
25	Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old. <i>Investigational New Drugs</i> , 2017, 35, 242-246.	2.6	20
26	Restoring Radioiodine Uptake in BRAF V600E-Mutated Papillary Thyroid Cancer. <i>Journal of the Endocrine Society</i> , 2017, 1, 285-287.	0.2	20
27	Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1433-1444.	3.3	19
28	Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers. <i>Investigational New Drugs</i> , 2018, 36, 156-162.	2.6	19
29	Redifferentiating Effect of Larotrectinib in <i>NTRK</i> -Rearranged Advanced Radioactive-Iodine Refractory Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 594-598.	4.5	19
30	Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2. <i>Anti-Cancer Drugs</i> , 2012, 23, 739-744.	1.4	18
31	Quantification of nivolumab in human plasma by LC-MS/HRMS and LC-MS/MS, comparison with ELISA. <i>Talanta</i> , 2021, 224, 121889.	5.5	18
32	Timing of palliative care needs reporting and aggressiveness of care near the end of life in metastatic lung cancer: A national registry-based study. <i>Cancer</i> , 2018, 124, 3044-3051.	4.1	17
33	Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients. <i>Clinical Nutrition</i> , 2020, 39, 1893-1899.	5.0	16
34	Lack of efficacy of neoadjuvant chemotherapy in adult patients with maxillo-facial high-grade osteosarcomas: A French experience in two reference centers. <i>Oral Oncology</i> , 2019, 95, 79-86.	1.5	15
35	Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial. <i>Thyroid</i> , 2019, 29, 1820-1827.	4.5	15
36	The prevalence of CT-defined low skeletal muscle mass in patients with metastatic cancer: a cross-sectional multicenter French study (the SCAN study). <i>Supportive Care in Cancer</i> , 2022, 30, 3119-3129.	2.2	14

#	ARTICLE	IF	CITATIONS
37	Is sarcopenia a missed factor in the management of patients with metastatic breast cancer?. <i>Breast</i> , 2022, 61, 84-90.	2.2	14
38	Patient-specific blood pressure correction technique for arterial stiffness: evaluation in a cohort on anti-angiogenic medication. <i>Hypertension Research</i> , 2017, 40, 752-757.	2.7	13
39	Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients. <i>Investigational New Drugs</i> , 2017, 35, 842-847.	2.6	13
40	Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 155-160.	1.9	13
41	Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients. <i>Clinical Therapeutics</i> , 2020, 42, 1302-1316.	2.5	13
42	Effects of acyl-coenzyme A binding protein (ACBP)/diazepam-binding inhibitor (DBI) on body mass index. <i>Cell Death and Disease</i> , 2021, 12, 599.	6.3	13
43	Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study. <i>Pharmaceuticals</i> , 2021, 14, 804.	3.8	13
44	Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib. <i>Oncotarget</i> , 2016, 7, 67507-67520.	1.8	13
45	A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1058, 102-107.	2.3	12
46	Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma. <i>Cancers</i> , 2020, 12, 931.	3.7	12
47	Resting energy metabolism and anticancer treatments. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2018, 21, 145-151.	2.5	11
48	A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients. <i>Pharmacological Research</i> , 2018, 136, 56-61.	7.1	11
49	Cancer during pregnancy: Factors associated with termination of pregnancy and perinatal outcomes. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 261, 110-115.	1.1	11
50	Antibiotics prescription to decrease progression-free survival (PFS) and overall survival (OS) in patients with advanced cancers treated with PD1/PDL1 immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3015-3015.	1.6	11
51	Integration of Oncology and Palliative Care, a Forgotten Indicator: Shared Decision-Making. <i>Oncologist</i> , 2015, 20, e26.	3.7	9
52	Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies. <i>Investigational New Drugs</i> , 2014, 32, 500-509.	2.6	8
53	Sorafenib for patients with differentiated thyroid cancer. <i>Lancet, The</i> , 2015, 385, 227-228.	13.7	8
54	Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort study. <i>Oncology Letters</i> , 2016, 11, 1859-1865.	1.8	8

#	ARTICLE	IF	CITATIONS
55	Everolimus and sunitinib as first- and second-line treatments of patients with metastatic papillary renal cell carcinoma (pRCC): A retrospective study of the GETUG (Groupe Français d'Étude des Tumeurs Glandulaires) Tj ETQq1 1 0.784314 rgBT /Over	1.6	8
56	Adapted physical activity in patients (Pts) with advanced pancreatic cancer (APACaP): Results from a prospective national randomized GERCOR trial.. Journal of Clinical Oncology, 2022, 40, 4007-4007.	1.6	8
57	Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2020, 86, 497-505.	2.3	7
58	Simultaneous quantification of dabrafenib, hydroxy-dabrafenib and trametinib in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2021, 193, 113718.	2.8	7
59	Predictive and prognostic value of systemic inflammatory response biomarkers in patients receiving nivolumab for metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 3055-3055.	1.6	7
60	Highly Specific Droplet-Digital PCR Detection of Universally Methylated Circulating Tumor DNA in Endometrial Carcinoma. Clinical Chemistry, 2022, 68, 782-793.	3.2	7
61	Preexisting Autoantibodies and Immune Related Adverse Events in Metastatic Urothelial Carcinoma Patients Treated by Pembrolizumab. Clinical Genitourinary Cancer, 2022, 20, e362-e368.	1.9	7
62	Analysis of Pembrolizumab in Human Plasma by LC-MS/HRMS. Method Validation and Comparison with Elisa. Biomedicines, 2021, 9, 621.	3.2	6
63	Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study. EBioMedicine, 2021, 73, 103630.	6.1	6
64	Energy expenditure profiles and the risk of early limiting toxicity in older patients with cancer: The ELCAPA-25 prospective cohort survey. Clinical Nutrition, 2022, 41, 1073-1082.	5.0	6
65	Sorafenib in Thyroid Cancer Patients: Learning From Toxicity. Oncologist, 2014, 19, e3.	3.7	5
66	Sorafenib for patients with differentiated thyroid cancer. Lancet, The, 2015, 385, 227.	13.7	5
67	Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals. European Journal of Cancer, 2016, 66, 75-82.	2.8	5
68	BRCA2 Loss-of-Function and High Sensitivity to Cisplatin-Based Chemotherapy in a Patient With a Pleomorphic Soft Tissue Sarcoma: Effect of Genomic Medicine. American Journal of the Medical Sciences, 2018, 356, 404-407.	1.1	5
69	Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. Cancers, 2019, 11, 762.	3.7	5
70	Results of the MARS study on the management of antiangiogenics'™ renovascular safety in ovarian cancer.. Journal of Clinical Oncology, 2013, 31, 5567-5567.	1.6	5
71	Sarcopenia and toxicity of the anti-PD1 inhibitors in real-life lung cancer patients: Results from the French Nationwide SCAN study.. Journal of Clinical Oncology, 2018, 36, e21066-e21066.	1.6	5
72	Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study. Endocrine Connections, 2018, 7, 1409-1414.	1.9	5

#	ARTICLE	IF	CITATIONS
73	Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer. <i>Gynecologic Oncology</i> , 2022, , .	1.4	5
74	Low-Dose Abiraterone Regimen: Drug Monitoring Might Be the Key. <i>Journal of Clinical Oncology</i> , 2018, 36, 3061-3062.	1.6	4
75	Lean Body Mass and Endocrine Status But Not Age Are Determinants of Resting Energy Expenditure in Patients with Non-Small Cell Lung Cancer. <i>Annals of Nutrition and Metabolism</i> , 2019, 75, 223-230.	1.9	4
76	Prevalence of drug-drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 741-751.	2.3	4
77	Severe skin rash during vemurafenib treatment: A predictive factor of early positive response in metastatic melanoma?. <i>Journal of Clinical Oncology</i> , 2014, 32, 9092-9092.	1.6	4
78	Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Étude des Tumeurs Uro-Génitales). <i>European Journal of Cancer</i> , 2021, 158, 1-11.	2.8	4
79	Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib Letter. <i>Clinical Cancer Research</i> , 2015, 21, 5639-5639.	7.0	3
80	Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer. <i>Lancet Oncology</i> , The, 2016, 17, e468.	10.7	3
81	Individualized Pazopanib Dosing Letter. <i>Clinical Cancer Research</i> , 2017, 23, 6377-6377.	7.0	3
82	Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone but decide wisely. <i>European Journal of Cancer</i> , 2020, 135, 51.	2.8	3
83	Angiotensin System Inhibitors in Renal Cell Carcinoma Letter. <i>Clinical Cancer Research</i> , 2016, 22, 524-524.	7.0	2
84	Cytidine Deaminase Activity Assessment to Select Perioperative Chemotherapy Regimen in Localized Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e493-e495.	1.9	2
85	Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2020.10.006 . <i>European Urology</i> , 2021, 79, e112.	1.9	2
86	First-in-human phase I and pharmacokinetic study of DTS-108 in patients with advanced carcinomas.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2557-2557.	1.6	2
87	Pharmacokinetics and pharmacodynamics of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma. <i>International Journal of Pharmacokinetics</i> , 2017, 2, 257-283.	0.5	1
88	RE: Associations Between Breast Cancer Survivorship and Adverse Mental Health Outcomes: A Systematic Review. <i>Journal of the National Cancer Institute</i> , 2019, 111, 335-336.	6.3	1
89	Management of Cancer Cachexia: ASCO Guideline Time to Address the Elephant in the Room. <i>Journal of Clinical Oncology</i> , 2020, 38, 3819-3819.	1.6	1
90	Impact of the COVID-19 pandemic on the management of cancer patients: the experience of the cancer outpatients department of a university hospital in Paris. <i>Clinical Medicine</i> , 2021, 21, e552-e555.	1.9	1

#	ARTICLE	IF	CITATIONS
91	Results of the MARS study on the management of antiangiogenics™ renovascular safety in breast cancer.. Journal of Clinical Oncology, 2013, 31, e12504-e12504.	1.6	1
92	How to predict sunitinib exposure and toxicity: A pharmacokinetic-pharmacodynamic study.. Journal of Clinical Oncology, 2013, 31, e15592-e15592.	1.6	1
93	Association of hypertension and proteinuria with overall survival in solid-tumor patients treated with anti-VEGF drugs in the MARS study.. Journal of Clinical Oncology, 2014, 32, 2548-2548.	1.6	1
94	Multidisciplinary risk assessment to reveal cancer treatments in complex cancer patients.. Journal of Clinical Oncology, 2014, 32, 170-170.	1.6	1
95	Burden of inpatient care and treatments in terminally-ill cancer patients: results from a population-based, retrospective study from administrative data in France.. Journal of Clinical Oncology, 2015, 33, 9527-9527.	1.6	1
96	Risk assessment of anticancer treatments beyond performance status: A prospective study in 277 cancer patients.. Journal of Clinical Oncology, 2015, 33, 9620-9620.	1.6	1
97	Goals and aggressiveness of care in metastatic lung cancer.. Journal of Clinical Oncology, 2016, 34, 10026-10026.	1.6	1
98	Renovascular Safety of Sunitinib in Renal Cell Carcinoma: The Prognostic Value of Hypertension and Proteinuria. Journal of Onco-Nephrology, 2017, 1, 213-219.	0.6	0
99	Management of antiangiogenics™ renovascular safety in ovarian cancer subgroup and intermediate results of the MARS study.. Journal of Clinical Oncology, 2012, 30, 5067-5067.	1.6	0
100	Management of antiangiogenics™ renovascular safety in breast cancer subgroup and intermediate results of the MARS study.. Journal of Clinical Oncology, 2012, 30, 1095-1095.	1.6	0
101	Arterial stiffness to predict hypertensive response to antiangiogenic drugs.. Journal of Clinical Oncology, 2013, 31, e13589-e13589.	1.6	0
102	Results of the MARS study on the management of antiangiogenics™ renovascular safety in colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 466-466.	1.6	0
103	Results of the MARS study on the management of antiangiogenics™ renovascular safety in renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 394-394.	1.6	0
104	Multidisciplinary risk assessment to reveal cancer treatments in unfit cancer patients.. Journal of Clinical Oncology, 2014, 32, 9551-9551.	1.6	0
105	Association of sunitinib exposure with toxicity outcome in a real-life population of elderly patients with cancer.. Journal of Clinical Oncology, 2014, 32, e20523-e20523.	1.6	0
106	Determinants for the decision of chemotherapy in advanced cancer patients.. Journal of Clinical Oncology, 2014, 32, 110-110.	1.6	0
107	End-of-life discussions with noncurable lung cancer patients: A patients' and oncologists' qualitative study.. Journal of Clinical Oncology, 2014, 32, 151-151.	1.6	0
108	Hypertension, proteinuria, and overall survival in elderly cancer patients treated with bevacizumab.. Journal of Clinical Oncology, 2014, 32, 186-186.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Pegylated liposomal doxorubicin-induced palmar plantar erythrodyesthesia: Identification of risks factors.. Journal of Clinical Oncology, 2015, 33, e13569-e13569.	1.6	0
110	Relationship between abiraterone plasma concentration and PSA response in metastatic castration resistant prostate cancer patients.. Journal of Clinical Oncology, 2015, 33, 5041-5041.	1.6	0
111	Is standard dose appropriate in elderly non-small cell lung carcinoma (NSCLC) patients treated with erlotinib?. Journal of Clinical Oncology, 2015, 33, 9537-9537.	1.6	0
112	Identification of candidates for sorafenib dose-escalation using sorafenib plasmatic concentration monitoring: Proof of concept.. Journal of Clinical Oncology, 2015, 33, 2572-2572.	1.6	0
113	Prevalence of malnutrition in PS 0-1 cancer patients: Results of the NutriCancer2 one-day national survey in 2,197 cancer patients.. Journal of Clinical Oncology, 2015, 33, 1587-1587.	1.6	0
114	Renovascular safety of sunitinib in prostate cancer: The prognostic value of hypertension and proteinuria.. Journal of Clinical Oncology, 2015, 33, e16056-e16056.	1.6	0
115	Feasibility of a multi-disciplinary rehabilitation program for post treatment cancer patients: A pilot study.. Journal of Clinical Oncology, 2015, 33, e20627-e20627.	1.6	0
116	Aggressiveness of care at the end of life in patients with localized and advanced bladder cancer.. Journal of Clinical Oncology, 2016, 34, 10029-10029.	1.6	0
117	Relationship between sarcopenia and dose-limiting toxicity (DLT) of sorafenib (SOR) in patients (pts) with advanced radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC) in the phase III DECISION trial.. Journal of Clinical Oncology, 2017, 35, e17594-e17594.	1.6	0
118	Association of muscle mass with pathologic response and toxicity in localized bladder cancer patients treated by neoadjuvant chemotherapy (NAC) and radical cystectomy (RC).. Journal of Clinical Oncology, 2017, 35, e16022-e16022.	1.6	0
119	Specific needs of non-visceral sarcoma patients: Evidence from an early multidisciplinary intervention.. Journal of Clinical Oncology, 2018, 36, e22133-e22133.	1.6	0
120	Metabolic profile and neoadjuvant chemotherapy sensitivity in high-grade bone sarcoma.. Journal of Clinical Oncology, 2019, 37, e22506-e22506.	1.6	0
121	Chapitre 23. Soins palliatifs en cancérologie. , 2020, , 613-633.		0
122	Reply to N Dominguez and T Canada. American Journal of Clinical Nutrition, 2017, 106, 958-959.	4.7	0